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Background. Opaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inﬂammatory properties, was shown to
inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro. We thus considered that opaganib could be beneﬁcial
for moderate to severe coronavirus disease 2019 (COVID-19) pneumonia. The objective of the study was to evaluate the safety of
opaganib and its effect on supplemental oxygen requirements and time to hospital discharge in COVID-19 pneumonia hospitalized
patients requiring supplemental oxygen.
Methods. This Phase 2a, randomized, double-blind, placebo-controlled study was conducted between July and December 2020
in 8 sites in the United States. Forty-two enrolled patients received opaganib (n = 23) or placebo (n = 19) added to standard of care
for up to 14 days and were followed up for 28 days after their last dose of opaganib/placebo.
Results. There were no safety concerns arising in this study. The incidence of ≥Grade 3 treatment-emergent adverse events was
17.4% and 33.3% in the opaganib and placebo groups, respectively. Three deaths occurred in each group. A numerical advantage for
opaganib over placebo was observed in in this nonpowered study reﬂected by total supplemental oxygen requirement from baseline
to Day 14, the requirement for supplemental oxygen for at least 24 hours by Day 14, and hospital discharge.
Conclusions. In this proof-of-concept study, hypoxic, hospitalized patients receiving oral opaganib had a similar safety proﬁle
to placebo-treated patients, with preliminary evidence of beneﬁt for opaganib as measured by supplementary oxygen requirement
and earlier hospital discharge. These ﬁndings support further evaluation of opaganib in this population.
Keywords. hospitalization; SARS-CoV-2; sphingosine-kinase-2; supplemental oxygen.
Acute pneumonia due to severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) infection leading to coronavirus
disease 2019 (COVID-19) can be life-threatening. Typical
symptoms of SARS-CoV-2 infection include fever, fatigue,
dry cough, and shortness of breath, but it can evolve to acute
respiratory distress syndrome. Among patients with
COVID-19, 80% present with symptoms of mild to moderate
severity, with or without pneumonia, whereas 5%–14% develop
serious or critical respiratory disease, requiring intensive care
unit support [1–3]. The mortality rate of COVID-19 ranges
from 0.1% to 19.7%, depending on country of origin, socioeconomic background, comorbidities such as diabetes and cardiovascular disease, and disease severity [4–8]. These
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comorbidities and advanced age (especially .65 years) increase
the risk of mortality [9, 10].
Patients who are hospitalized with COVID-19 often require
supplemental oxygen to maintain adequate oxygenation [3, 9].
Some pharmacological agents (corticosteroids and remdesivir)
have been widely used as standard of care (SoC), with remdesivir ﬁrst approved in the United States for emergency use in
hospitalized COVID-19 patients in May 2020 [11].
Opaganib (RedHill Biopharma) is a ﬁrst-in-class orally available, small molecule, selective sphingosine kinase-2 (SK-2) inhibitor with antiviral and anti-inﬂammatory properties [12].
Multiple ongoing clinical trials are evaluating opaganib as therapy for cancer. The antiviral effect of opaganib was demonstrated in various preclinical studies. Reid et al [13] showed that
decreased expression or pharmacologic inhibition of SK-2 signiﬁcantly inhibited Chikungunya virus replication. In a work
by Xia et al [14], opaganib was shown to reduce fatality rates
from inﬂuenza A infection in mice. Moreover, in a preliminary
study using an in vitro model of human bronchial tissue, we recently demonstrated that opaganib has potent antiviral activity
against SARS-CoV-2 [15]. We hypothesized that the antiviral
and anti-inﬂammatory effects of opaganib would be beneﬁcial
for the treatment of SARS-CoV-2 infection, particularly for patients with moderate to severe COVID-19 pneumonia
Opaganib in COVID-19 Pneumonia • OFID • 1
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METHODS
Design

This was a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, parallel arm, placebo-controlled study conducted in 8 sites in the United States. The study was not powered
for efﬁcacy. Eligible patients received opaganib or matching
placebo twice daily added to SoC (per regional, institutional/
physician practices). Eligible participants were adults (18–80
years inclusively), with SARS-CoV-2 infection determined by
polymerase chain reaction analysis in a nasopharyngeal sample
and pneumonia determined by chest x-ray. The full list of eligibility criteria is provided in the Supplementary Data, Section-1.
Intervention

Participants were randomized 1:1 to receive 2 × 250 mg of opaganib oral capsules or matching placebo every 12 hours for up
to 14 days (Days 1–14). This dose had been determined in a
Phase 1 clinical study in oncology patients as the maximum
safe and tolerable dose [17]. Patients discharged before or at
Day 10 completed only 10 days of treatment. After their last
study drug dose, participants were followed for up to 28 days
(safety follow-up). Treatment assignments remained blinded
to the patients, investigators, hospital staff, and sponsor
(RedHill Biopharma). The clinical trial (ClinicalTrials.gov
Identiﬁer NCT 04414618) was performed in accordance with
the Declaration of Helsinki (1964), as revised most recently
in Seoul (2008), US Food and Drug Administration (FDA) regulations, and the ICH Guideline for Good Clinical Practice,
E6(R1) and local rules and regulations.
Outcomes

Given the exploratory nature of this proof-of-concept study, we
sought to evaluate several clinically meaningful outcomes. We
designed a primary outcome measure comparing total supplemental oxygen requirements from baseline to Day 14 (area under the curve) using daily oxygen ﬂow measurements. Primary
endpoint details are provided in the Supplementary Data,
Section-2, together with a complete list of secondary, post
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hoc, safety, and exploratory endpoints. Presented herein are
the safety outcomes, that is, incidence of treatment-emergent
adverse events (TEAEs) and serious TEAEs (TESAEs) over
the safety follow-up period, as well as the following clinically
relevant secondary outcomes: (1) time to 50% reduction from
baseline in supplemental oxygen requirement by Day 14,
(2) percentage of patients no longer receiving supplemental oxygen for at least 24 hours by Day 14, (3) time to intubation and
mechanical ventilation by Day 14, and (4) mortality by Day 30.
The post hoc outcomes were as follows: (1) percentage of patients no longer receiving supplemental oxygen for at least
24 hours by Day 14 per SoC regimen, (2) time to intubation
and mechanical ventilation by safety follow-up, (3) mortality
by safety follow-up, (4) incidence of hospital discharge by
Day 14 and by safety follow-up, and (5) time to ≥2 points improvement in the World Health Organization (WHO) Ordinal
Scale [18] by Day 14.
Statistics

Because the sample size (40 patients) was not chosen for statistical consideration, efﬁcacy interpretation is based on numerical comparisons of descriptive statistics. Statistical
methodology details are provided in the Supplementary Data,
Section-3. Baseline characteristics are presented for the
intent-to-treat (ITT) population (all randomized patients).
Safety evaluations were performed for the safety population
(patients who took at least 1 dose of study drug). Efﬁcacy endpoints were analyzed for the modiﬁed ITT (mITT) population
(patients who took at least 1 dose of study drug).
Patient Consent Statement

Written consent was obtained from all patients who participated in this study. The design of the study has been approved by
local ethical committees and by the national regulatory agencies in all the countries where the protocol was activated including the FDA, the Israeli Ministry of Health, and the Argentine
Administration of Medicines, Food and Medical Technology.
RESULTS

A diagram of the study ﬂow is presented in Figure 1. The ITT
population comprised 42 eligible patients, enrolled in
July–November 2020. Of these, 23 patients were randomized
to receive opaganib and 19 patients were randomized to
receive placebo (randomization details are provided in the
Supplementary Data, Section-4. One patient in each group
did not receive study drug and was excluded from the safety
and mITT populations. One patient randomized to placebo
was mistakenly given opaganib on Days 10 and 11.
Demographic and Other Baseline Characteristics

The main demographic and baseline characteristics of patients
in the ITT population are presented in Table 1. Most patients

Downloaded from https://academic.oup.com/ofid/article/9/7/ofac232/6583599 by Henry Ford Hospital user on 22 August 2022

requiring supplemental oxygen. In a small cohort of patients
with severe COVID-19 pneumonia, in which opaganib was offered through compassionate use, it appeared to improve clinical and laboratory parameters, and it was safe and well
tolerated [16].
This Phase 2a proof-of-concept study was designed to provide a preliminary evaluation of the safety and efﬁcacy of opaganib when added to SoC in hospitalized patients with
COVID-19 pneumonia who required supplemental oxygen.
Aside from safety and tolerability assessments, efﬁcacy endpoints measured included change in oxygen requirements
and clinical improvement parameters.

were male (64.3%) with an overall median age of 58.0 years.
Randomization resulted in a difference between the opaganib
and placebo arms in median age (years; 52.0 and 61.0, respectively) and median baseline oxygen requirement (L/minute; 6.0
and 10.5, respectively). The median time (days) from onset of
symptoms to randomization was 10.0 for the opaganib group
and 9.0 for placebo.
Remdesivir and/or high-dose corticosteroids (dexamethasone, prednisone, and methylprednisolone) comprised known
effective SoC for COVID-19 and were coadministered with
opaganib in 22 (95.7%) patients, and with placebo in all 18
(100%) patients. This included remdesivir in 10 (43.5%) patients on opaganib and 9 (50.0%) on placebo, and high-dose
corticosteroids in 21 (91.3%) and all 18 (100%) patients,
respectively.
Treatment Compliance

Compliance was assessed in a subset of the safety population
comprising 21 patients on opaganib and 18 patients on placebo

(further details are provided in the Supplementary Data,
Section-5). For 2 patients on opaganib, compliance was not deﬁned: for the patient randomized to placebo who took opaganib
on one day, the expected number of opaganib doses was zero;
the second patient was lost to follow-up, and thus compliance
could not be assessed. The mean (+standard deviation) compliance was 90.05% (+21.523) in the opaganib and 98.41%
(+3.917) in the placebo groups, respectively.
Treatment-Emergent Adverse Events

The incidence of TEAEs was similar between groups (52.2%, in
the opaganib group versus 50.0% in the placebo group)
(Table 2). In general, each unique TEAE term was reported
singly by 1 patient (either in the opaganib or placebo group).
The only TEAEs reported by 2 patients (8.7% in the
opaganib group), and with a higher incidence in the
opaganib group than in placebo, were hypokalemia (reported
in 1 patient on placebo) and diarrhea (not reported in patients
on placebo).
Opaganib in COVID-19 Pneumonia • OFID • 3
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Figure 1. Study ﬂow diagram. mITT, modiﬁed intent-to-treat population.

Table 1. Main Patient Demographic and Baseline Characteristics in the Opaganib and Placebo Groups and Overall, and Kaplan-Meier Estimate of the
Cumulative Incidence of No Longer Receiving Supplemental Oxygen for at Least 24 Hours by Day 14 in the Opaganib and Placebo Groups per
Standard-of-Care Regimen of Interest
Placebo (N = 19)

Overall (N = 42)

52.0 (29–80)

61.0 (35–80)

58.0 (29–80)

,70

20 (87.0)

15 (78.9)

35 (83.3)

≥70

3 (13.0)

4 (21.1)

7 (16.7)

16 (69.6)

11 (57.9)

27 (64.3)

7 (30.4)

8 (42.1)

15 (35.7)

12 (52.2)

8 (42.1)

20 (47.6)

18 (78.3)

15 (78.9)

33 (78.6)

1 (4.3)

1 (5.3)

2 (4.8)

-

1 (5.3)

1 (2.4)

Black or African American

3 (13.0)

2 (10.5)

Other

1 (4.3)

Parameter (ITT Population)
Age (years), median (range)

Opaganib (N = 23)

Age (years), n (%)

Gender, n (%)
Male
Ethnicity, n (%)
Hispanic or Latino
Race, n (%)
White
American Indian or Alaska Native
Asian

5 (11.9)

-

1 (2.4)

Smoking Status, n (%)
Never

20 (87.0)

14 (73.7)

34 (81.0)

Former

2 (8.7)

4 (21.1)

6 (14.3)

Current

1 (4.3)

1 (5.3)

2 (4.8)

,6.5

13 (56.5)

10 (52.6)

23 (54.8)

≥6.5

10 (43.5)

9 (47.4)

19 (45.2)

HbA1c (%) at Screening, n (%)

Weight at baseline (Kg), median (range)a

104.33 (74.8–163.3)

79.00 (55.3–140.0)

96.76 (55.3–163.3)

Oxygen Requirement at Baseline (L/minute)
n
Median (min, max)
Time from symptoms onset to hospitalization (days), median (range)b
Time from symptoms onset to randomization (days), median (range)b

22
6.0 (0, 40)
7.0 (−4 to 39)
10.0 (4–41)

18
10.5 (1, 55)

40
6.0 (0, 55)

6.5 (0–11)

7.0 (−4 to 39)

9.0 (2–18)

9.0 (2–41)

Time from diagnosis to hospitalization (days), median (range)

0.0 (−5 to 20)

0.0 (−1 to 14)

0.0 (−5 to 20)

Time from diagnosis to randomization (days), median (range)

4.0 (1–33)

4.0 (2–18)

4.0 (1–33)

Kaplan-Meier Estimate of the Cumulative Incidence of No Longer Receiving Supplemental Oxygen for at Least 24 Hours by Day 14: Standard-of-Care Regimen
Groupc,d
Overall (N)
Cumulative incidence at Day 14
Treated with combination of remdesivir and high-dose corticosteroids (N)
Cumulative incidence at Day 14
Treated only with high-dose corticosteroids (N)
Cumulative incidence at Day 14

22

18

50.00

22.22

9
44.44
11
54.55

9
22.22
9
22.22

Abbreviations: HbA1c, hemoglobin A1c; ITT, intent-to-treat population.
a

Two patients in each group had missing information on weight at baseline, resulting in n = 21 patients in the opaganib group and n = 17 patients in the placebo group.
One patient in the placebo group had missing information on symptoms onset, resulting in n = 18 patients in the placebo group.

b
c

The number of patients treated with speciﬁc standard-of-care regimen is presented.

d

Death was censored at 14 days.

The TESAEs were reported in 13.0% of patients on opaganib
and 27.8% patients on placebo. The TESAEs by Medical
Dictionary for Regulatory Activities System Organ Class included
the following: infections and infestations (8.7% in the opaganib
and 11.1% in the placebo group); respiratory, thoracic, and mediastinal disorders (8.7% and 16.7%, respectively); and renal and urinary disorders (4.3% and 11.1%, respectively). None of the
TESAEs were deemed as treatment related by the investigator.
The TEAEs of Grade 3 and above were reported in 4 patients
(17.4%) on opaganib and 6 patients (33.3%) on placebo, with no
4 • OFID • Winthrop et al

TEAEs of Grade 3 and above reported at a higher frequency in
the opaganib group compared with placebo (Table 2).
Treatment-related TEAEs were recorded in 2 patients in the opaganib group, including 1 patient with Grade 1 diarrhea and 1 patient with Grade 3 rash. Both events were nonserious, and in both
cases, the drug was withdrawn, and the patients recovered.
There were no reported TEAEs resulting in dose reductions.
The TEAEs leading to treatment withdrawal were reported in 4
patients (17.4%) in the opaganib group (including a case of
Grade 1 heart palpitations [not related to study treatment], a
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Female

Table 2. TEAEs by MedDRA Preferred Term in the Opaganib and
Placebo Groups (Safety Population)

Safety Population

Opaganib
(N = 23)
n (%)a

Placebo
(N = 18)
n (%)a

Any TEAE

12 (52.2)

9 (50.0)

Any TEAE Grade 3 and above

4 (17.4)

6 (33.3)

Any Serious TEAE

3 (13.0)

5 (27.8)

Any treatment-related TEAE

2 (8.7)

-

Any treatment-related Grade 3 and above TEAE

1 (4.3)

-

-

-

Any treatment-related serious TEAE
MedDRA Preferred Term

n (%)

n (%)

Anemia

1 (4.3)

1 (5.6)

COVID-19 pneumonia

1 (4.3)

1 (5.6)

Sepsis

1 (4.3)

-

-

1 (5.6)

Septic shock
Fibrin D dimer increased

1 (4.3)

-

-

1 (5.6)

White blood cell count increased

-

1 (5.6)

Glucose tolerance impaired

-

1 (5.6)

Hypocalcemia

-

1 (5.6)

Acute kidney injury

1 (4.3)

2 (11.1)

Respiratory failure

2 (8.7)

2 (11.1)

-

1 (5.6)

Troponin I increased

Pneumonia aspiration
Rash

1 (4.3)

-

Shock

-

1 (5.6)

Abbreviations: COVID-19, coronavirus disease 2019; MedDRA, Medical Dictionary for
Regulatory Activities; TEAEs, treatment-emergent adverse events.
a

The n refers to number of patients with the respective TEAEs, not number of TEAEs.

b

A total of 8 Grade 3 and above TEAEs were recorded in 4 patients in the opaganib arm, and
13 Grade 3 and above TEAEs were recorded in 6 patients on placebo, with some patients
experiencing multiple TEAEs.

case of Grade 1 diarrhea [possibly related to study treatment], a
case of Grade 4 sepsis and Grade 4 acute kidney injury [both
unlikely related to study treatment], and a case of Grade 3
rash [possibly related to study treatment]) and 1 patient
(5.6%) in the placebo group, who suffered from multiple
TEAEs resulting in drug withdrawal.
Three death cases were reported in each group, which occurred due to (1) COVID-19 pneumonia, sepsis, and respiratory failure in the opaganib arm and (2) acute kidney injury and
respiratory failure (2 cases) in placebo. None of the deaths were
assessed by the investigator as related to the treatment.
In addition to the safety analysis, several efﬁcacy analyses
(presented below) were performed with the aim of providing
initial data on potential beneﬁcial effects of opaganib in the
study population. Because the study was not powered for efﬁcacy, the ﬁndings from these analyses provide a preliminary
evaluation of opaganib’s potential beneﬁts, and they should
be regarded as such.

Requirement of Supplemental Oxygen by Day 14

The cumulative incidence for no longer requiring supplemental
oxygen for at least 24 hours by Day 14 was estimated using the
Kaplan-Meier analysis. The analysis showed a higher estimated
cumulative incidence in patients on opaganib (50%) compared
with those on placebo (22.2%) (Supplementary Figure 2, Table 1).
The subgroup analysis based on SoC regimen showed consistent ﬁndings in patients on high-dose corticosteroids and patients on remdesivir and corticosteroids (Table 1).
Speciﬁcally, the estimated cumulative incidence of no longer
receiving supplemental oxygen by Day 14 in patients receiving
opaganib on top of remdesivir in combination with high-dose
corticosteroids, and in those receiving opaganib on top of highdose corticosteroids only, was consistent with that observed in
the overall opaganib group and higher than in the respective
subgroups receiving placebo on top of the SoC (44.4% versus
22.2% and 54.6% versus 22.2%, respectively).
The median Kaplan-Meier estimated time to 50% reduction
from baseline in supplemental oxygen requirement based
on oxygen ﬂow (L/minute) Day 1–Day 14 was 5 days in the opaganib versus 8 days in the placebo group. The Kaplan-Meier estimated cumulative incidence of this event by Day 14 was 81%
in the opaganib group compared to 66.7% in the placebo group.
Intubation and Mechanical Ventilation, and Mortality During the Course
of the Study and at the End of Follow-up

The Kaplan-Meier estimated cumulative incidence of intubation and mechanical ventilation at Day 14 was 9.6% in the opaganib group and 11.1% in placebo. There were 2 intubation and
mechanical ventilation events in each group, and there were no
subsequent intubations and mechanical ventilations through
the end of safety follow-up.
Three patients on opaganib and 2 patients on placebo died by
Day 30. The Kaplan-Meier estimated cumulative incidence of
death by Day 30 was 15.0% in the opaganib and 11.9% in the placebo group. An additional death occurred in the placebo group
by the end of safety follow-up. The Kaplan-Meier estimated cumulative incidences of death by safety follow-up were 15.0% and
19.2% in the opaganib and placebo groups, respectively.

Total Supplemental Oxygen Requirement Using the Maximal Daily Oxygen
Flow Over 14 Days

Hospital Discharge

A relative beneﬁt derived for each group was calculated (as described in the Supplementary Data, Section-2). The relative

The Kaplan-Meier estimated cumulative incidence of hospital
discharge was 68.2% in the opaganib and 50.0% in the placebo
Opaganib in COVID-19 Pneumonia • OFID • 5
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TEAEs Grade 3 and Above by MedDRA Preferred Termb

beneﬁt calculated was 61.6% for opaganib (n = 21) and 46.7%
for placebo (n = 18) (Supplementary Figure 1). This was a
post hoc analysis to the predeﬁned primary endpoint;
as more information on the course of COVID-19
pneumonia became available, this endpoint, namely, quantifying total supplemental oxygen required over time (across various devices), proved to be of less clinical value than initially
anticipated.

groups by Day 7 and 86.4% and 55.6%, respectively, by Day 14
(Supplementary Figure 3). A related post hoc analysis, whereby
the 2-point improvement in the WHO Ordinal Scale was derived for patients, is presented in Supplementary Table 1.

DISCUSSION

6 • OFID • Winthrop et al

Limitations

The main limitation of this study is its small sample size, which
allows for descriptive analyses rather than meaningful statistical interpretation. A further limitation is the imbalance in age
and supplemental oxygen requirement at baseline, which is a
result of the small sample size despite randomization. The clinical interpretation of the primary endpoint was limited, as described under Discussion, leading to the addition of post hoc
analyses to help with the overall interpretation of the data.
An additional limitation of the study is that certain predeﬁned
secondary endpoints that relied on inpatient data collection
could not be assessed due to changing standard of practice leading to earlier discharge of patients than anticipated at the time
of protocol development. Furthermore, discharge criteria were
somewhat subjective, depending on hospital capacity and regulations. It is notable that a greater proportion of patients on
opaganib versus placebo were discharged before Day 14.
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This proof-of-concept study explored the safety and effectiveness of oral opaganib in hospitalized patients with
COVID-19 pneumonia requiring supplemental oxygen.
Opaganib’s safety proﬁle in this study was not materially different than that of placebo. Results suggest that clinical improvement, as measured by reduced need for supplemental oxygen,
improved WHO level in the scale for clinical improvement
and in time to discharge (Supplementary Table 2).
Several lines of preliminary evidence suggested that opaganib may be particularly relevant to COVID-19 therapy.
Before the onset of the COVID-19 pandemic, opaganib had
demonstrated antiviral and anti-inﬂammatory effects in several
preclinical models, including the following: amelioration of
Pseudomonas aeruginosa-induced lung injury and reduction
of fatality rates from inﬂuenza infection [19, 20]; inhibition
of host inﬂammatory responses in several disease models [21,
22]; and exertion of various effects on the immune system
[23]. Opaganib has since been shown to have potent antiviral
activity against SARS-CoV-2 in a preclinical study using an
in vitro model of human bronchial tissue [15] and was associated with favorable outcomes when offered through compassionate use to patients with moderate to severe COVID-19
pneumonia requiring supplemental oxygen via high-ﬂow nasal
cannula [16]. Because opaganib targets a host cell factor rather
than the virus directly, development of resistance is less likely.
This is of particular interest in SARS-CoV-2 infection, given its
rapidly emerging mutations and viral strains.
The antiviral agent remdesivir has been approved for treatment in certain stages of COVID-19; however, it is administered intravenously and lacks anti-inﬂammatory properties
[5], whereas opaganib is an oral agent with both antiviral and
anti-inﬂammatory properties. Moreover, opaganib is stable at
room temperature for 5 years (RedHill Biopharma Ltd., unpublished data, 2022). These factors support opaganib as a muchneeded, practical, and convenient potential treatment of
COVID-19 pneumonia.
Opaganib was shown to be well tolerated in this study, with
no new safety signals emerging. The only TEAE of Grade 3 and
above reported at a higher frequency in the opaganib group
than placebo was a Grade 3 rash in a single patient, which resolved upon stopping study drug. Rash is a known uncommon
toxicity of opaganib. Three patients on opaganib and 5 patients
on placebo experienced TESAEs. The TEAEs leading to treatment withdrawal were reported in 17.4% of patients on opaganib and 5.6% of patients on placebo. By the safety follow-up

timepoint, there were 3 deaths recorded in each group, and
none were deemed treatment related. The overall incidence
of TEAEs and TESAEs were similar in both treatment groups.
The current study was not powered for efﬁcacy, and, as such,
its efﬁcacy ﬁndings provide a preliminary evaluation of opaganib’s beneﬁcial effects in the study population. A numerical
superiority was found for opaganib over placebo across several
clinical outcomes. The prespeciﬁed primary efﬁcacy analysis of
change in total supplemental oxygen requirements proved difﬁcult to analyze and required a post hoc analysis utilizing percentage change. This post hoc analysis demonstrated an
apparent difference, with less total supplemental oxygen requirement for patients on opaganib compared with those on
placebo. As the pandemic progressed, improvement in supplemental oxygen requirement had become a commonly used criterion for hospital discharge in COVID-19 patients [24].
Hence, the predeﬁned secondary analysis of no longer
requiring supplemental oxygen for at least 24 hours was
the most clinically relevant endpoint. A number of other prespeciﬁed and post hoc analyses measuring clinical beneﬁt supported the improvement in oxygen requirements. Of note,
however, there was an imbalance in median age between the
2 arms of the study, with a younger population in the opaganib
group (52.0 years) compared with placebo (61.0 years). In addition, the mean baseline oxygen requirement (L/minute)
was lower in the opaganib group (6.0) than in placebo (10.5).
Because younger individuals are expected to have generally better disease outcomes than their older counterparts, we cannot
rule out that these imbalances may have impacted the preliminary efﬁcacy results of the study, contributing to opaganib’s
observed beneﬁt in the studied population. However, such potential impact remains hypothetical, because most studies looking at the effect of age on disease severity report the age of .65
years as a risk factor.

CONCLUSIONS
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Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to beneﬁt the reader, the
posted materials are not copyedited and are the sole responsibility of the
authors, so questions or comments should be addressed to the corresponding author.
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